262 related articles for article (PubMed ID: 20006922)
1. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management.
Izzedine H; Massard C; Spano JP; Goldwasser F; Khayat D; Soria JC
Eur J Cancer; 2010 Jan; 46(2):439-48. PubMed ID: 20006922
[TBL] [Abstract][Full Text] [Related]
2. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
3. Renal effects of anti-angiogenesis therapy: update for the internist.
Gurevich F; Perazella MA
Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension.
Izzedine H; Rixe O; Billemont B; Baumelou A; Deray G
Am J Kidney Dis; 2007 Aug; 50(2):203-18. PubMed ID: 17660022
[TBL] [Abstract][Full Text] [Related]
5. [Nephrotoxicity--proteinuria and hypertension--].
Ando M
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1649-53. PubMed ID: 18931564
[TBL] [Abstract][Full Text] [Related]
6. Biology of anti-angiogenic therapy-induced thrombotic microangiopathy.
Eremina V; Quaggin SE
Semin Nephrol; 2010 Nov; 30(6):582-90. PubMed ID: 21146123
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
[TBL] [Abstract][Full Text] [Related]
9. VEGF inhibition and renal thrombotic microangiopathy.
Nochy D; Lefaucheur C; Hill G
N Engl J Med; 2008 Jul; 359(2):206; author reply 206-7. PubMed ID: 18618951
[No Abstract] [Full Text] [Related]
10. Management of hypertension in angiogenesis inhibitor-treated patients.
Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
[TBL] [Abstract][Full Text] [Related]
11. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management.
Tesařová P; Tesař V
Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524
[TBL] [Abstract][Full Text] [Related]
12. Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats.
Fujimura T; Yamagishi S; Ueda S; Fukami K; Shibata R; Matsumoto Y; Kaida Y; Hayashida A; Koike K; Matsui T; Nakamura K; Okuda S
Nephrol Dial Transplant; 2009 May; 24(5):1397-406. PubMed ID: 19042927
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy.
Chen S; Lee JS; Iglesias-de la Cruz MC; Wang A; Izquierdo-Lahuerta A; Gandhi NK; Danesh FR; Wolf G; Ziyadeh FN
Nephrol Dial Transplant; 2005 Jul; 20(7):1320-8. PubMed ID: 15840669
[TBL] [Abstract][Full Text] [Related]
14. VEGF inhibition and renal thrombotic microangiopathy.
Eremina V; Jefferson JA; Kowalewska J; Hochster H; Haas M; Weisstuch J; Richardson C; Kopp JB; Kabir MG; Backx PH; Gerber HP; Ferrara N; Barisoni L; Alpers CE; Quaggin SE
N Engl J Med; 2008 Mar; 358(11):1129-36. PubMed ID: 18337603
[TBL] [Abstract][Full Text] [Related]
15. [Renal toxicity of anti-VEGF (corrected) targeted therapies].
Vigneau C; Rioux-Leclercq N
Nephrol Ther; 2013 Jun; 9(3):174-9. PubMed ID: 23410950
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth.
Liang XB; Ma LJ; Naito T; Wang Y; Madaio M; Zent R; Pozzi A; Fogo AB
J Am Soc Nephrol; 2006 Jul; 17(7):1886-95. PubMed ID: 16790514
[TBL] [Abstract][Full Text] [Related]
17. Proteinuria and VEGF-targeted therapies:
an underestimated toxicity?
Izzedine H; Soria JC; Escudier B
J Nephrol; 2013; 26(5):807-10. PubMed ID: 24052461
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Izzedine H; Mangier M; Ory V; Zhang SY; Sendeyo K; Bouachi K; Audard V; Péchoux C; Soria JC; Massard C; Bahleda R; Bourry E; Khayat D; Baumelou A; Lang P; Ollero M; Pawlak A; Sahali D
Kidney Int; 2014 Feb; 85(2):457-70. PubMed ID: 24067439
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
20. [Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors].
Rollino C; Beltrame G; Ferro M; Quattrocchio G; Tonda L; Quarello F
G Ital Nefrol; 2010; 27 Suppl 50():S70-4. PubMed ID: 20922699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
